everyone. Oliver. Hello, Thanks,
Our a quarter of was fueled market. focus growth result high was of by validation strategy recall seventh to record This the consecutive our Reconstruction performance. on
over This of revenue this which all-time will of over segment. valuable XX% the increase year of million seeing to market $XX.X add last important long-term pre-pandemic accounts quarter year. and the our growth. QX of will also XX%. has ‘XX of Recon over of share XX% record sales go with as hospitals Reconstruction The We're market, cosmetic share now a efficiencies. quarter and improved operational high company continue year market in thrilled We're The the farms for set also reemergence back We foundation in increased an result hit highly same we to to support channel. margins had Augmentation grow had this increase XX% market, gross
of the As beyond, ‘XX focusing and key we'll into on look we're three rest areas.
share and Reconstruction within First, Augmentation. accelerate market growth
Second, for invest in an future to growth. plastic lastly, support to offering transform surgeons. current continue to into enhanced company, R&D Sientra And innovative aesthetics portfolio commercial and and
our of perform ‘XX. accounts and in revenue drove XX% existing more continue to well than Our extremely QX
accounts New had of profile a indicator a XXX also over growth to accounts quarter ‘XX. the as leading long-term served first in and new we
it in tissue order the volumes. four major are in in receives for to it new GPO sales expanders takes record reminder now six typically significant a As bring every country, account, to before a months
and to is in and to best Augmentation are the backed The share portfolio XX choice be benefits both top accounts of which of partner implants. plastic our This surgeons. to be new for which our is warranty led growth Sientra’s our fact the our value unique expanders beyond. proposition, Sientra. accounts by safety line year products, surgeons Recon tissue accretive to and switching We and growth the data, the by innovative and and Driven reinforces the technologies expect profile and the games, clinical have those continues breast year class acceleration offers this for on which
where the boom The now and a in seasonality. pandemic to resetting surgery purposely quarter volume. quite an about market hit XX% set we market. our share compared grow X.X%. last will year commercial to our of to continue And market. plastic the Augmentation our turning the strategy, Augmentation returned same and by up Last to to this high market this caused working all-time we're And Now surgeons quarter our of normal year, ourselves seeing are
few the growing number brand awareness in putting the almost two rate highest the consumer the over category, years, and all position our double at also in past While us brands.
which to We’re sanitary is profile, surgeons brand about driving for consumers investing plastic to educate safety implants. our requests strategically
also growing which Additionally, fat management, our in grafting acquire market, year. practice at on are only seeing the Surgeon our partners, to We're surgery XX plastic producing segments grafting not business decision them novel advantages growing the fat providing but and and value of to product revenue end validates plastic Augmentation. our in last the of interest about highest techniques, surgery, technology but breast the more their
of to call and We're we year turn very build this obtain years. confident We're predictable grafting reliable discussed surgery about couple a aesthetics the sessions, and foundation technology but of surgeons natural, patients a surgery the fat a benefits highlighted safe, that, fat offer been both aesthetic a for also plastic of ago, has upcoming topic unique use recent The and over Andy. was in as breast I'll meeting topic recall excited of weeks outcomes. San the Just to the many and grafting publications. Diego. fat growing for the grafting highly of benefits With to
